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Abstract
Sustained pressure overload leads to compensatory myocardial hypertrophy and subsequent heart failure, a leading cause
of morbidity and mortality. Further unraveling of the cellular processes involved is essential for development of new
treatment strategies. We have investigated the hypothesis that the transmembrane Z-disc proteoglycan syndecan-4, a co-
receptor for integrins, connecting extracellular matrix proteins to the cytoskeleton, is an important signal transducer in
cardiomyocytes during development of concentric myocardial hypertrophy following pressure overload. Echocardiographic,
histochemical and cardiomyocyte size measurements showed that syndecan-4
2/2 mice did not develop concentric
myocardial hypertrophy as found in wild-type mice, but rather left ventricular dilatation and dysfunction following pressure
overload. Protein and gene expression analyses revealed diminished activation of the central, pro-hypertrophic calcineurin-
nuclear factor of activated T-cell (NFAT) signaling pathway. Cardiomyocytes from syndecan-4
2/2-NFAT-luciferase reporter
mice subjected to cyclic mechanical stretch, a hypertrophic stimulus, showed minimal activation of NFAT (1.6-fold)
compared to 5.8-fold increase in NFAT-luciferase control cardiomyocytes. Accordingly, overexpression of syndecan-4 or
introducing a cell-permeable membrane-targeted syndecan-4 polypeptide (gain of function) activated NFATc4 in vitro. Pull-
down experiments demonstrated a direct intracellular syndecan-4-calcineurin interaction. This interaction and activation of
NFAT were increased by dephosphorylation of serine 179 (pS179) in syndecan-4. During pressure overload, phosphorylation
of syndecan-4 was decreased, and association between syndecan-4, calcineurin and its co-activator calmodulin increased.
Moreover, calcineurin dephosphorylated pS179, indicating that calcineurin regulates its own binding and activation. Finally,
patients with hypertrophic myocardium due to aortic stenosis had increased syndecan-4 levels with decreased pS179 which
was associated with increased NFAT activation. In conclusion, our data show that syndecan-4 is essential for compensatory
hypertrophy in the pressure overloaded heart. Specifically, syndecan-4 regulates stretch-induced activation of the
calcineurin-NFAT pathway in cardiomyocytes. Thus, our data suggest that manipulation of syndecan-4 may provide an
option for therapeutic modulation of calcineurin-NFAT signaling.
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Introduction
Sustained pressure overload leads to compensatory myocardial
hypertrophy and subsequent decompensation and heart failure, a
leading cause of morbidity and mortality. Mechanical stimuli,
circulating hormones, as well as autocrine and paracrine factors
are involved in initiating myocardial hypertrophy. Transduction
of mechanical stimuli may involve molecules that bind the
extracellular matrix to the cytoskeleton, but exactly which
molecules participate is still unknown. Further unraveling of
such signaling pathways is essential for defining novel therapeutic
targets.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28302We have previously shown increased myocardial mRNA
expression of all four members of the syndecan family and increased
protein levels of syndecan-4 in the hypertrophic non-infarcted
region of the left ventricle following myocardial infarction [1].
Syndecan-4 is a transmembrane proteoglycan that connects
extracellular matrix proteins to the cardiomyocyte cytoskeleton
[2], and has been localized to costameres and Z-discs [3], potentially
important sites for signal transduction across the membrane [4,5].
Moreover, syndecan-4is a co-receptor for severalgrowth factors [6].
Various intracellular signaling pathways have been implicated in
transduction of mechanical stimuli during induction of cardiac
hypertrophy, including mitogen-activated protein kinase (MAPK)
cascades, protein kinase C (PKC)-mediated signaling [7–9] and the
calcineurin-nuclear factor of activated T-cell (NFAT) pathway [10].
Interestingly, syndecan-4 has been shown to bind and regulate
localization and activity of one of these, namely PKC-a [11].
We hypothesized that syndecan-4 acts as a signal transducer in
cardiomyocytes responding to an increase in mechanical stress on
the myocardium with subsequent activation of pro-hypertrophic
signaling. In this study, we show that syndecan-4 is essential for
development of concentric myocardial hypertrophy by acting as a
scaffolding protein for mechanical stretch-induced activation of
the calcineurin-NFAT pathway.
Results
Lack of syndecan-4 inhibits development of concentric
myocardial hypertrophy during pressure overload
Syndecan-4
2/2 mice had normal cardiac dimensions and
function compared to wild-type (WT) mice (Table S1). Three
weeks after inducing pressure overload by aortic banding (AB), WT
developed concentric left ventricular (LV) hypertrophy manifested
as a significant increase in posterior wall thickness (Fig. 1A–C). In
contrast, syndecan-4
2/2 mice displayed no increase in wall
thickness following AB (Fig. 1A–C), but a significant increase in
LV cross-sectional (Fig. 1D) and longitudinal diameter compared to
sham-operated syndecan-4
2/2 mice (syndecan-4
2/2-SHAB) and
WT-AB (Table S1). LV dilatation in syndecan-4
2/2-AB was
paralleled by reduced cardiac function compared to WT-AB, as
indicated by reduced LV fractional shortening (Fig. 1E). Accord-
ingly, syndecan-4
2/2-AB exhibited increased lung weight and left
atrial diameter, as well as increased levels of angiotensin II in serum
compared to WT-AB (Tables S1 and S2).
In agreement with the observed lack of concentric hypertrophy,
cardiomyocyte width was unchanged in syndecan-4
2/2-AB
compared to syndecan-4
2/2-SHAB (Fig. 1F), whereas in WT-
AB cardiomyocyte width was increased by 25% compared to WT-
SHAB. The cardiomyocytes were longer in both WT-AB (8%) and
syndecan-4
2/2-AB (10%) compared to respective controls.
LV histological sections demonstrated less densely packed
cardiomyocytes in syndecan-4
2/2 compared to WT after both
SHAB and AB (Fig. 1G). This finding was confirmed by
transmission electron microscopy, as syndecan-4
2/2 hearts
exhibited wider, irregular gaps between adjacent cardiomyocytes,
in addition to disorganized Z-lines, compared to WT following
both SHAB and AB (Fig. 1H). Myocardial wet weight was
significantly increased in syndecan-4
2/2 compared to WT only
following AB (Table S2). These data demonstrate increased
extracellular space in syndecan-4
2/2-AB compared to WT-AB, in
which concentric myocardial hypertrophy with wider cardiomy-
ocytes dominated. Immunohistochemical examination showed
equal staining for collagen type I (Fig. 1G), and immunoblotting
showed similar changes in collagen I, III and VIII following AB in
both genotypes (Table S2).
The lack of cardiomyocyte hypertrophy in syndecan-4
2/2 mice
was associated with lower expression of cardiac markers of
hypertrophy (Fig. 1I–J). Expression of a-skeletal actin, previously
shown to correlate with myocardial hypertrophy [12] was lower in
syndecan-4
2/2-AB than in WT-AB (Fig. 1I). Expression of B-type
natriuretic peptide (BNP), which has been shown to be regulated
by the transcription factor NFAT [13,14] and associated with
myocardial hypertrophy, was attenuated in syndecan-4
2/2-AB
compared to WT-AB (Fig. 1J). Expression of atrial natriuretic
peptide (ANP) was increased after AB, but there were no
differences between the two genotypes (Fig. 1K). Expression of
regulator of calcineurin 1–4 (RCAN1-4; also known as MCIP1), a
direct target for NFAT [14–16], was significantly lower in
syndecan-4
2/2-AB compared to WT-AB (Fig. 1L), indicating
reduced NFAT activity in syndecan-4
2/2 mice after AB. Both the
reduction in RCAN1-4 and in BNP are consistent with inhibition
of the calcineurin-NFAT pathway, as they have been shown to be
direct targets of NFAT in cardiomyocytes [14].
NFAT signaling is inhibited in syndecan-4
2/2 mice
To study the role of syndecan-4 in pro-hypertrophic NFAT
activation, NFAT phosphorylation (pNFAT) and NFAT luciferase
reporter activity were investigated in pressure overloaded hearts
and isolated cardiomyocytes subjected to mechanical stress and
autonomous hypertrophy. The calcineurin-dependent NFAT
isoform c4 (NFATc4) has previously been found to be sufficient
for cardiac hypertrophy [13] and to be activated in the
hypertrophic human myocardium [17], and thus activation of
this isoform was investigated in our study. Syndecan-4
2/2 mice
demonstrated reduced NFATc4 activation compared to WT
following AB, shown as increased pNFATc4 levels (Fig. 2A).
Increased levels of pNFAT indicate inhibition of the calcineurin-
NFAT pathway, since dephosphorylation of these transcription
factors by calcineurin is necessary for translocation to the nucleus.
Following sham-operation, there was a minimal reduction in
NFAT activation in syndecan-4
2/2 hearts.
To study whether syndecan-4 acts as a mechanotransducer for
activation of calcineurin-NFAT signaling in the pressure over-
loaded heart, cardiomyocytes were subjected to cyclic mechanical
stretch. In NFAT-luciferase reporter cardiomyocytes, 24 hrs of
mechanical stretch was sufficient to induce significant calcineurin-
dependent NFAT activation (Fig. S1A–B). Importantly, syndecan-
4
2/2-NFAT luciferase cardiomyocytes showed minimal activation
of NFAT (1.6-fold) compared to a 5.8-fold increase in NFAT-
luciferase control cells following mechanical stretch (Fig. 2B).
Accordingly, pNFATc4 levels were significantly higher in
syndecan-4
2/2 cardiomyocytes than in WT cells following
mechanical stretch (Fig. 2C). Finally, the role of syndecan-4 in
calcineurin-NFAT activation in cardiomyocytes subjected to
autonomous hypertrophy, was investigated. Syndecan-4
2/2
cardiomyocytes subjected to autonomous hypertrophy [18]
showed significantly higher levels of pNFATc4 compared to WT
cardiomyocytes (Fig. 2D), with a corresponding lower level of
NFAT activation as measured by luciferase activity in syndecan-
4
2/2-NFAT luciferase cells (Fig. 2E) and a reduced hypertrophic
response as measured by radioactive leucine-incorporation after
five days in culture (Fig. 2F). Altogether our data indicate that pro-
hypertrophic NFAT signalling was inhibited in cardiomyocytes
lacking syndecan-4.
Overexpression of membrane-localized syndecan-4 in
vitro activates NFAT
Increased levels of full-length syndecan-4 in the membrane of
HEK-293 cells caused diminished cytoplasmic pNFATc4 levels
Syndecan-4 Regulates Calcineurin-NFAT Signaling
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28302(Fig. 3A, upper panel) and reduced cytoplasmic/increased nuclear
NFAT levels (second panel from top), indicating that increased
syndecan-4 levels in the membrane induce NFAT activation by
dephosphorylation and translocation to the nucleus. To evaluate
syndecan-4 as a regulator of intracellular NFAT activation in
cardiomyocytes, we generated a cell-permeable peptide consisting
of the membrane and cytoplasmic regions of syndecan-4.
Cardiomyocytes treated with this peptide in vitro showed complete
dephosphorylation of NFATc4, while total amount was unaltered
(Fig. 3B), consistent with membrane-localized syndecan-4 being
important for NFAT activation through its intracellular domain in
cardiomyocytes. To evaluate if membrane localization of synde-
can-4 is important for NFAT activation, NFAT-luciferase
cardiomyocytes were treated with a cell-permeable peptide
consisting only of the cytoplasmic region of syndecan-4. This
peptide significantly reduced NFAT-luciferase activity (Fig. 3C),
indicating that NFAT activation is inhibited when syndecan-4 is
soluble, and not localized in the surface membrane.
We also investigated levels of enzymes that have been reported
to regulate NFAT phosphorylation in pressure overloaded hearts,
and hence may be involved in the syndecan-4-mediated NFAT
activation. There was, however, no difference in the level of
calcineurin in WT and syndecan-4
2/2 hearts after AB (Fig. S2 A).
Glycogen synthase kinase (GSK) 3-b phosphorylated by Akt is
known to antagonize calcineurin action and development of
cardiac hypertrophy by phosphorylating NFAT [19–21]. Both
GSK3-b and Akt were phosphorylated to the same extent in the
two genotypes following AB (Fig. S2 B–D). It has also been shown
that each of the three main branches of mitogen-activated kinases
(MAPK) directly modulates calcineurin-NFAT signaling and
hypertrophic response in the heart [22]. However, activation of
extracellular signal regulated protein kinase (ERK) 1/2, c-jun N-
terminal kinases (JNK) 2/3 and p38 was comparable in WT and
syndecan-4
2/2 hearts following AB (Fig. S2 E–J). Thus, lack of
syndecan-4 did not influence the calcineurin level, GSK-3b or
MAPK activation, suggesting that another mechanism regulating
NFAT phosphorylation was responsible for the activation of
NFAT by syndecan-4. As syndecan-4 is known to directly interact
with signaling molecules [23], we hypothesized that syndecan-4
interacts directly with calcineurin.
Figure 2. Decreased activation of the calcineurin-nuclear factor of activated T-cell (NFAT) pathway in syndecan-4
2/2 mice in
response to aortic banding. (A) Phosphorylated NFATc4 (pNFATc4) and NFATc4 levels in the left ventricle of wild-type (WT) and syndecan-4
2/2
(Syn-4
2/2) mice 24 h after aortic banding (AB) or sham-operation (SHAB) analyzed by immunoblotting. An NFAT-rich cell lysate (Ramos) was used as
control for NFAT-positive protein bands (n=5–15). (B) Luciferase (luc) activity in neonatal cardiomyocytes from NFAT-luciferase and Syn-4
2/2-NFAT-
luciferase mice subjected to 24 h of cyclic mechanical stress (MS) (n=12–33). (C) pNFATc4 levels in WT and Syn-4
2/2 neonatal cardiomyocytes
subjected to 24 h of cyclic MS (n=9–12). (D) pNFATc4 and NFATc4 levels in neonatal cardiomyocytes from Syn-4
2/2 and WT mice subjected to
autonomous hypertrophy (n=4). (E) Luciferase activity in neonatal cardiomyocytes from NFAT-luciferase and Syn-4
2/2-NFAT-luciferase mice
subjected to autonomous hypertrophy (n=9–18). (F) Radioactive leucine incorporation in Syn-4
2/2 and WT mice subjected to five days of
autonomous hypertrophy (n=6–24). GAPDH and actin were used for loading control. Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g002
Figure 1. Lack of syndecan-4 inhibits development of concentric hypertrophy three weeks after induction of pressure overload. (A)
Representative cross-sections (HE staining) of the hearts of wild-type (WT) and syndecan-4
2/2 (Syn-4
2/2) mice after sham operation (SHAB) or aorta
banding (AB) (n=3). Scale bars, 0.1 mm. (B) Representative 2D and M-mode tracings from the left ventricle (LV) (LVDd, LV diameter in diastole) (n=9–
10). Echocardiographic measurements of (C) posterior wall thickness in diastole (PWd) and (D) LVDd normalized to tibia length (TL), and (E) LV
fractional shortening (LVFS) (n=9–10). (F) Cardiomyocyte width (3 animals in each group). (G) Representative sections of LV myocardium stained for
collagen I (brown staining indicates collagen I) (n=2–3). Scale bars, 100 mm. (H) Representative transmission electron microscopy images of LV
myocardium (n=2). Scale bars, 5 mm. Arrows indicate intercellular spaces and arrowheads indicate Z-lines. Real-time PCR analysis of (I) a-skeletal actin
(a-ska), (J) B-type natriuretic peptide (BNP), (K) atrial natriuretic peptide (ANP) and (L) regulator of calcineurin 1–4 (RCAN1-4). mRNA levels were
normalized to GAPDH in LV (n=10). Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28302Calcineurin associates with syndecan-4, and the
association is regulated by dephosphorylation of serine
179 in syndecan-4 during pressure overload
To examine whether calcineurin associates with syndecan-4, pull-
down experiments using biotinylated peptides spanning the
cytoplasmic part of syndecan-4 were performed. Recombinant
His-triggerfactor (TF)-calcineurinsubunit A (CnA) was pulled down
with syndecan-4 and to a lesser extent with syndecan-2 (Fig. 4A,
alignment of syndecan-2 and 4 shown in Fig. 4B). Then, syndecan-4
and CnA were co-transfected into HEK-293 cells and immunopre-
cipitated with syndecan-4 (Fig. 4C; epitope mapping of syndecan-4
antibodies shown in Fig. S3) and CnA (Fig. 4D) antibodies.
Figure 3. Membrane-localized syndecan-4 activates nuclear factor of activated T-cell (NFAT) in vitro. Phosphorylated NFATc4 (pNFATc4),
NFATc4 and syndecan-4 levels in (A) HEK-293 cells overexpressing full-length HA-tagged syndecan-4 (HA-syn-4, Cyt=cytoplasmic, Nuc=nuclear,
Mem=membrane, EGFR=epidermal growth factor receptor (marker of membrane fraction)) (n=12). Wild-type (WT) cardiomyocytes treated with a
cell-permeable peptide consisting of the membrane and cytoplasmic parts of syndecan-4 (syn-4 (mem+cyt)-HA) (n=4), analyzed by immunoblotting
(B), and NFAT-luciferase reporter cardiomyocytes treated with a cell-permeable peptide consisting of the cytoplasmic part of syndecan-4 only,
analyzed by luciferase activity (n=3) (C). GAPDH, histone H4, EGFR and actin were used as loading controls. Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g003
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28302Immunoblotting revealed the presence of co-immunoprecipitated
CnA (Fig. 4C, upper panel) and syndecan-4 (Fig. 4D, upper panel).
Phosphorylation of serine 179 (pS179) in the intracellular domain
of syndecan-4 has been shown to regulate protein interactions, such
asPKCaassociation[24].Pull-downexperimentsusingbiotinylated
peptides spanningeitherthenon-phosphorylated or phosphorylated
cytoplasmic part of syndecan-4 showed that less recombinant His-
TF-CnA bound to pS179-syndecan-4 than to non-phosphorylated
Figure 4. Association of syndecan-4 with calcineurin A (CnA). (A) Pull-down experiments with biotinylated peptides covering cytoplasmic
domains of syndecan-1–4 were performed using recombinant His-trigger factor (TF)-CnA, and precipitates immunoblotted for presence of His-TF-CnA
(n=3). (B) Alignment of syndecan-4 and syndecan-2. Black boxes indicate similar amino acids within consensus region. Lysates from HEK-293 cells co-
transfected with syndecan-4 and CnA subjected to immunoprecipitation with (C) anti-syndecan-4 (n=3) or (D) anti-CnA (n=3) were immunoblotted
with anti-CnA or anti-syndecan-4, respectively. Pull-down experiments with biotinylated peptides covering non-phosphorylated or phosphorylated
cytoplasmic part of syndecan-4 were performed using recombinant His-TF-CnA (E) or left ventricular (LV) tissue before immunoblotted for presence
of endogenous CnA (n=3) and PKC-a (n=2) (F). (G) LV tissue extracts from WT-SHAB and WT-AB were immunoprecipitated with anti-syndecan-4 or
control IgG and lysates and immunoprecipitates immunoblotted for presence of PKC-a, CnA and calmodulin (CaM, n=2). (H) Relative pS179-
syndecan-4/total syndecan-4 levels in aorta-banded (AB) versus sham-operated (SHAB) WT LV tissue (n=3). Calsequestrin was used for loading
control. Values are mean 6 s.e.m.
doi:10.1371/journal.pone.0028302.g004
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28302syndecan-4 (Fig. 4E). Furthermore, endogenous CnA in LV tissue
was pulled down with the non-phosphorylated form, but only
minimally with pS179-syndecan-4 (Fig. 4F). As expected, less PKCa
bound to pS179-syndecan-4.
In immunoprecipitation experiments using LV tissue, more co-
precipitation of CnA with syndecan-4 was observed after AB
compared to sham (Fig. 4G). Furthermore, co-immunoprecipita-
tion of the CnA co-activator calmodulin and PKCa were also
increased after AB (Fig. 4G). Since pS179 appeared to inhibit
syndecan-4-CnA association, pS179-syndecan-4 levels were ana-
lyzed following AB using a specific pS179-syndecan-4 antibody.
pS179-syndecan-4 levels were found to be reduced by 40% in
WT-AB versus WT-SHAB, favoring CnA-syndecan-4 association
following AB (Fig. 4H). In the murine heart, syndecan-4 was
identified as separate bands at ,20–24 kDa consistent with
reported sizes of syndecan-4 protein [25].
Consistent with phosphorylation of syndecan-4 being a
regulator of CnA association, expression of S179E-syndecan-4
(mimicking constitutive S179 phosphorylation) increased pNFAT
levels compared to WT syndecan-4 and was similar to non-
transfected cells (Fig. 5A). Conversely, expression of S179A-
syndecan-4 (mimicking no S179 phosphorylation) reduced
pNFATc4 levels compared to non-transfected cells and WT
syndecan-4 expression (Fig. 5A), indicating that membrane-bound
syndecan-4 is an activator of CnA.
Finally, co-transfection of syndecan-4 and CnA into HEK-293
cells resulted in reduced pS179 levels compared to syndecan-4
transfection alone, indicating that calcineurin regulates its own
binding and activation by dephosphorylation of syndecan-4
(Fig. 5B).
Intracellular V- and C2-regions in syndecan-4 bind to the
autoinhibitory domain of calcineurin
The cytoplasmic region of syndecan-4 consists of three regions;
two that are conserved between the syndecans, C1 and C2, and
the isoform-specific V-region (Fig. 6A). Alignment of syndecan-4
with other CnA-binding proteins; NFAT [26], AKAP79 [27] and
calcineurin inhibitor (cain) [28], revealed a putative CnA-binding
motif (PIxIxIT) in the V-region (Fig. 6B). The cytoplasmic region
of syndecan-4 was synthesized as overlapping 20-mer peptides on
a membrane overlayed with active CnA or endogenous calci-
neurin in tissue lysate followed by immunoblotting. Strongest
CnA-binding was observed in the amino acid sequence
SYDLGKKPIYKKAPTNEFYA, which contains the PIxIxIT–
similar motif and the C2-region (Fig. 6C, amino acids 179–198,
underlined).
To identify the syndecan-4 binding region, full-length CnA
protein was synthesized as 20-mer peptides and overlayed with a
biotin-syndecan-4 (171–198) peptide followed by anti-biotin-
peroxidase conjugated immunoblotting. Syndecan-4 binding was
located to the autoinhibitory domain in CnA (Fig. 6D, middle
panel and Fig. 6E). Consistent with our other data, a biotin-
phospho-peptide (pS179-syndecan-4) bound only minimally to
CnA (Fig. 6D, right panel).
Figure 5. Level of phosphorylated syndecan-4 regulates NFAT activation and is decreased by calcineurin. (A) Phosphorylated NFATc4
(pNFATc4), NFATc4 and syndecan-4 levels in HEK-293 cells transfected with HA-syn-4, HA-syn-4-S179A (mimicking no S179 phosphorylation) or HA-
syn-4-S179E (mimicking constitutive S179 phosphorylation) (n=6–9) and (B) pS179-syndecan-4, syndecan-4 and calcineurin A (CnA) levels in HEK-293
cells co-transfected with CnA and HA-syn-4 or HA-syn-4 alone (n=6) analyzed by immunoblotting. Actin was used a loading control. Values are mean
6 s.e.m.
doi:10.1371/journal.pone.0028302.g005
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28302Increased myocardial syndecan-4 levels and reduced
serine 179 phosphorylation in patients with aortic
stenosis
In order to demonstrate a direct relevance to human heart
disease, we examined levels of syndecan-4 and syndecan-4
phosphorylation in biopsies taken peroperatively from patients
with hypertrophic myocardium due to aortic stenosis and controls.
We found a 92 and 72% increase in syndecan-4 mRNA and
protein levels, respectively, in patients with aortic stenosis, with a
corresponding 21% reduction in pS179-syndecan-4/total synde-
can-4 ratio and a 197% increase in RCAN1-4 mRNA (Fig. 7 A–
C), indicating a state that favors calcineurin-NFAT activation in
the hypertrophic human heart.
Discussion
Our main findings are that syndecan-4
2/2 mice did not develop
concentric hypertrophy in response to chronic pressure overload,
and that lack of syndecan-4 specifically inhibited the calcineurin-
NFAT pathway in vivo and in vitro. In particular, NFAT activation
was almost totally inhibited following stretch of syndecan-4
2/2
cardiomyocytes, whereas it was substantially increased in wild-type
cardiomyocytes in response to stretch. Syndecan-4 was shown to
bind to the autoinhibitory domain in calcineurin, and this binding
was enhanced by dephosphorylation of S179 in syndecan-4
(depicted in Fig. 8). Finally, dephosphorylation of syndecan-4
occurred during pressure overload both in mice and man.
Activation of the calcium- and calmodulin-dependent phospha-
tase calcineurin is necessary and sufficient to induce pathological
cardiac hypertrophy [13,29–32]. Calcineurin dephosphorylates
the transcription factors belonging to the NFAT family, leading to
their activation [13]. Most studies inhibiting calcineurin activity
have produced a significant attenuation of pathological hypertro-
phy [32], which is in accordance with our in vivo findings including
lack of concentric hypertrophy during pressure overload in
syndecan-4
2/2 mice.
Figure 6. V- and C2-region in syndecan-4 bind to the autoinhibitory domain in calcineurin A (CnA). (A) Schematic illustration of the
three cytoplasmic regions in syndecan-4. (B) Alignment of syndecan-4 with other calcineurin binding motifs. Identification of PIxIxIT-similar motif
(6represents any amino acid) in V-region. Black boxes indicate similar amino acids within the consensus region. (C) Syndecan-4 residues important for
CnA binding were identified by overlaying an array of immobilized syndecan-4 20-mer peptides with 4 amino acids offset with recombinant CnA (left
panel). (D) CnA residues important for syndecan-4 binding were identified by overlaying an array of immobilized CnA peptides with 3 amino acids
offset with a biotinylated peptide covering the cytoplasmic region of syndecan-4 (middle panel) or the phosphoform (pS179, right panel).
Immunoblots without pre-incubation with CnA (C, right panel) or biotinylated peptide (D, left panel) were used as negative controls. Underlined
amino acids indicate those relevant for CnA-syndecan-4 binding. Overlay experiments were performed three times with similar results. (E) Schematic
illustration of various interaction domains in CnA. Autoinhibitory domain is defined to amino acids 467–491 [53].
doi:10.1371/journal.pone.0028302.g006
Figure 7. Increased myocardial syndecan-4 levels and reduced serine 179 phosphorylation (pS179) in patients with aortic stenosis.
(A) Real-time PCR analysis of syndecan-4 (n=9), (B) immunoblots of pS179-syndecan-4 (top panel) and syndecan-4 (bottom panel) levels with relative
syndecan-4 and pS179-syndecan-4/syndecan-4 ratios (n=3) and real-time PCR analysis of regulator of calcineurin 1–4 (RCAN1-4) (n=7) (C) in
myocardial biopsies from patients with severe aortic stenosis (AS) versus control patients. GAPDH was used for loading control. Values are mean 6
s.e.m.
doi:10.1371/journal.pone.0028302.g007
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response to increased mechanical stress, and regulators of the
calcineurin-NFAT pathway are only partially known. It has been
suggested that mechanical signals in cardiomyocytes converge on
membrane proteins such as integrins [33,34]. In addition, studies
indicate a role for mechanotransducer complexes involving the Z-
discs and related proteins [35,36]. As syndecan-4 connects the
extracellular matrix proteins to the cytoskeleton, is a co-receptor
with a5b1 integrin [37] and is localized to costameres and Z-discs
[3], we hypothesized that syndecan-4 senses mechanical stress and
activates pro-hypertrophic signaling responses such as the
calcineurin-NFAT pathway. A role for syndecan-4 as a mechan-
otransducer has previously been suggested by us [1] and others
[38]. We demonstrate that following stretch, NFAT activation was
nearly abolished in cardiomyocytes lacking syndecan-4. We also
show that lack of syndecan-4 reduced NFAT activation and
expression of the NFAT target gene RCAN1-4 during increased
mechanical stress induced by left ventricular pressure overload.
These data clearly indicate that syndecan-4 is a regulator of NFAT
activity in cardiomyocytes in response to increased mechanical
stress.
We then studied the mechanism for activation of calcineurin-
NFAT signaling by syndecan-4, and showed that CnA binds
directly to the intracellular V- and C2-regions in syndecan-4. The
V-region confers binding specificity for each syndecan family
member and the syndecan-4 V-region contains a PIxIxIT-similar
motif. A loosely conserved PIxIxIT motif has been suggested to
represent the CnA binding site in AKAP79 [27], NFATs [26], cain
[28,39] and RCAN1-4 [16,40]. The syndecan-4 binding region
was located to the autoinhibitory domain of CnA. This domain is
thought to block the active site within the catalytic region of CnA,
rendering the phosphatase inactive [41–43]. Increased syndecan-
4-calmodulin co-precipitation was observed during pressure
overload. Calmodulin has been found to increase calcineurin
activity more than 20-fold. Interestingly, the PDZ domain of
CASK, which is known to bind calmodulin, is also able to bind to
the C2 region of syndecans [44]. Thus, a direct interaction
between CnA and syndecan-4 might facilitate activation of
calcineurin by bringing calmodulin and CnA in close proximity.
We also demonstrated that CnA-syndecan-4 interaction is
regulated by phosphorylation of S179 in syndecan-4. During
cardiac pressure overload, we found a decrease in phosphorylated
S179-syndecan-4 and an increased association between syndecan-
4 and calcineurin, suggesting that dephosphorylation of pS179-
syndecan-4 causes increased binding of calcineurin. More directly,
we showed that expression of a construct mimicking absent S179
phosphorylation (S179A) increased NFAT activity. These results
indicate that alterations in syndecan-4 phosphorylation level may
have functional significance for development of cardiac hypertro-
phy. Moreover, the significantly reduced myocardial phosphory-
lation of S179-syndecan-4/total syndecan-4 ratios combined with
increased NFAT activation found in patients with aortic stenosis
indicates a direct relevance for this mechanism in human heart
disease. Interestingly, a reduction in phosphorylation of S179 in
syndecan-4 was induced by overexpression of CnA, suggesting that
calcineurin dephosphorylates syndecan-4 in vivo and thereby
regulates its own activity.
Concentric hypertrophy of the myocardium during pressure
overload is considered to be a compensatory response of the heart
to deal with increased afterload during such conditions as aortic
stenosis and hypertension. Lack of compensatory hypertrophy
may thus cause myocardial dilatation and possibly dysfunction.
Accordingly, Meguro et al. [45] showed that inhibition of
calcineurin-NFAT activation with cyclosporine attenuated pres-
sure overload hypertrophy and enhanced the susceptibility to heart
failure. Similarly, we found reduced cardiac function and
attenuated concentric hypertrophy in syndecan-4
2/2-AB. Al-
though our data clearly indicate syndecan-4-mediated, pro-
Figure 8. Schematic illustration of proposed syndecan-4-CnA interaction. Phosphorylation of S179 in syndecan-4 renders the CnA-NFAT
pathway inactive (left box). Dephosphorylation of syndecan-4 induces binding of CnA and calmodulin (CaM) to syndecan-4 and subsequent
activation of the NFAT transcription factor (right box).
doi:10.1371/journal.pone.0028302.g008
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may also mediate other effects in the pressure-overloaded heart. In
a recent study, syndecan-4
2/2 mice were shown to have impaired
cardiac function and increased mortality following myocardial
infarction [46], while in another study, cardiac function was
improved and NFAT activation increased in syndecan-4
2/2 mice
after infarction [47], suggesting additional layers of complexity in
syndecan-4-dependent NFAT regulation and remodeling of the
heart.
In summary, our data show that syndecan-4 is essential for
development of compensatory myocardial hypertrophy in the
pressure overloaded myocardium. Specifically, syndecan-4 reg-
ulates stretch-induced activation of the pro-hypertrophic calci-
neurin-NFAT signaling pathway in cardiomyocytes. Syndecan-4
was found to bind to the autoinhibitory domain of calcineurin
and this binding was regulated by phosphorylation of syndecan-
4. Patients with aortic stenosis exhibited decreased pS179-
syndecan-4/syndecan-4 ratios, indicating a direct relevance to
human myocardial hypertrophy. In conclusion, our data indicate
that syndecan-4 is a scaffolding protein for activation of
calcineurin-NFAT signaling and development of concentric
myocardial hypertrophy during pressure overload, both in mice
and man.
Methods
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996) and was
approved by the Norwegian National Animal Research Commit-
tee (permit of approval number STFDU1736). The human
myocardial biopsy protocol was approved by the Regional
Committee for Research.
Ethics in Eastern Norway (permit of approval number
1.2005.316) and conforms to the Declaration of Helsinki.
Animal model and transthoracic echocardiography
Banding of the ascending aorta was carried out in 7 week old
WT (C57BL/6, Møllergaard, Denmark) and syndecan-4
2/2 mice
[48]. Anaesthesia was induced with .5% isoflurane gas and
,95% O2 in a gas chamber, followed by tracheostomy and
ventilation with 2% isoflurane and 98% O2, with a tidal volume of
350 ml and a respiratory frequency of 160 min
21 on a MiniVent
ventilator (Harvard Apparatus, Holliston, MA 01746, USA). A
sternal split of the cranial 1/3 of the sternum was performed and
an 8-0 silk ligature was tied around the ascending aorta and a 26G
blunted needle, which was subsequently removed. Sham-operated
animals underwent the same procedure without banding of the
aorta. After twenty-one days echocardiography was carried out
using a VEVO 2100 (Visualsonics, Toronto, Canada) before the
animals were sacrificed. Echocardiographic examinations were
performed under standardized conditions with the animals in the
supine position, spontaneously breathing 1.5% isoflurane and
98.5% O2 on a mask. Echocardiographic data were analyzed off-
line using VEVO 2100 1.1.0 software from Visualsonics. Three
representative cycles were analyzed and averaged. Two-dimen-
sional (2D) images of the LV were obtained both in long and short
axes. Short axis recordings were obtained at the level of the
papillary muscle. M-mode tracings were recorded at the level of
both the papillary muscles and the aortic valves, with 2D
guidance. LV wall thickness and cavity dimensions were measured
through the largest diameter of the ventricle both in systole and
diastole. LV fractional shortening (LVFS) in percent, was
calculated using the following formula.
LVFS~ LVDd{LVDs ðÞ =LVDd|100
where LVDd is LV diameter in diastole, and LVDs is LV diameter
in systole. Doppler recordings were obtained in the left parasternal
long axis position. Pulsed wave Doppler was used for measuring
flow velocities across the constriction, as well as in the left
ventricular outflow tract (LVOT) and in the mitral annulus.
Cardiac output (CO) was calculated in LVOT using the following
equation
CO~LVOT VTI|p| diameter=2 ðÞ
2|HR
where VTI is the velocity time integral, HR is heart rate and
diameter is measured in LVOT.
The LV, right ventricular free wall and lungs were weighed and
normalized to tibia length. Only mice with a maximum flow
velocity across the stricture .3 m/s and ,4 m/s 24 hours after
AB and .4 m/s and ,6 m/s three weeks after AB were included
(mean values, 4.360.1 m/s in syndecan-4
2/2 mice versus
4.360.1 m/s in WT).
LV pressure measurements
Immediately after finishing echocardiography, a 1.4-Fr microtip
pressure transducer catheter (SPR-671, Millar Instruments,
Houston, TX) was introduced into the left ventricle through the
right carotid artery for measurements of LV pressures and
calculations of its maximal positive and negative first derivatives.
Data recorded from 10–15 consecutive beats were analyzed. LV
pressure measurements were performed in un-operated WT and
syndecan-4
2/2 mice, and not following AB as the aortic
constriction was too tight to allow for retrograde insertion of the
catheter.
Estimation of LV fluid content
Three weeks after AB or SHAB LV from WT and syndecan-
4
2/2 mice were weighed immediately upon dissection, cut into
pieces and dried for 24 h at 90uC, before weighing again.
Angiotensin II concentration in plasma
Plasma was extracted from full-blood containing 0.44 mM o-
phenanthroline, 25 mM EDTA, 1 mM p-hydroxy-mercuriben-
zoic acid and 0.12 mM pepstatin A and the concentration of
angiotensin II was measured using the Max Human Angiotensin 2
ELISA Kit according to the manufacturers protocol (EA3501-1,
Assaypro, St. Charles, MO) in WT and syndecan-4
2/2 mice three
weeks after AB or SHAB.
Human myocardial biopsies
LV apical myocardial biopsies (10 mg) were obtained immedi-
ately before crossclamping the aorta in twelve patients with severe
aortic stenosis and twelve control patients with coronary artery
disease during elective aortic valve replacement and coronary
artery bypass operations, respectively. Biopsies were taken from a
normal appearing and contracting area using a 22G needle (Easy
Core Biopsy System, Boston Scientific International S.A., Cedex,
France). Patients 40–85 years old with symptomatic aortic stenosis,
a mean aortic gradient .50 mmHg or an aortic valve area
,0.7 cm
2, and without significant coronary artery disease were
included in the aortic stenosis group. Patients 40–85 years old with
stable angina pectoris, no known previous myocardial infarction,
ejection fraction .50%, and without significant valve disease were
included in the control group. The patients had no chest pain or
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tively. Informed written consent was obtained from each patient.
NFAT-luciferase mice
TheNFAT-luciferasemice havenine copiesofanNFAT-binding
site from the interleukin (IL)-4 promoter (59-TGGAAAATT-39)
inserted upstream of the luciferase reporter gene, driven by the a-
myosinheavy chainpromoter[31], and werea kind gift from Jeffery
D. Molkentin (Cincinnati Children’s Hospital Medical Center,
University of Cincinnati, Cincinnati, OH). Neonatal mice from the
progeny were used for isolation of cardiomyocytes.
Syndecan-4
2/2-NFAT luciferase mice
Syndecan-4
2/2-NFAT luciferase reporter mice were generated
by crossing syndecan-4
2/2 mice with the NFAT-luciferase mice.
Neonatal mice from the progeny were used for isolation of
cardiomyocytes.
Quantification of luciferase activity
For measurements of luciferase activity, cardiomyocytes were
harvested according to the Luciferase Assay System protocol
(E1500, Promega) and luminescence from sample duplicates was
quantified on a Victor 3 1420 Multilabel Counter (PerkinElmer,
Waltham, MA).
Adult cardiomyocyte isolation and cell size
measurements
Cardiomyocytes were enzymatically isolated from WT and
syndecan-4
2/2 mice three weeks after AB or SHAB (n=3 in each
group) by cannulating the aorta and retrogradely perfusing with a
Ca
2+-free Tyrode’s solution containing 0.05 mg/ml collagenase
(Yakult, Tokyo, Japan) for 10 min. The left ventricle was then
removed and minced, cardiomyocytes precipitated, and extracel-
lular [Ca
2+] was gradually increased. Cells were stored at room
temperature until use. Cell length and width measurements were
determined in a genotype-blinded manner from 2-dimensional
images of randomly selected cells.
Electron microscopy
Two hearts from WT and syndecan-4
2/2 mice, respectively,
obtained three weeks after AB or SHAB were perfused with 2.0%
glutaraldehyde buffered in 0.2 M cacodylate at pH 7.4 for
15 min. LV blocks (about 1 mm
3) were fixed in 2% glutaralde-
hyde in cacodylate buffer for 2 h, rinsed overnight and transferred
to a 1% OsO4 solution for 30 min on ice. After rinsing in
cacodylate, the specimens were dehydrated in graded ethanols and
embedded in Epon. Ultrathin sections (60–100 nm) were stained
with uranyl acetate and lead citrate and examined and
photographed in a Tecnai G2 spirit BioTWIN 120 kV, LaB6,
Transmission Electron Microscope with 4 k Eagle camera (FEI
Company, Eindhoven, The Netherlands). All images were
examined by two investigators, blinded for mouse identity.
Histology
Hearts fixed in formalin were processed into paraffin wax. Six 4
mm thick slices were cut along the short axis from the mid-
ventricular level of each tissue sample. Slices were stained with
hematoxylin-eosin for morphology.
Immunohistochemistry
The excised hearts were placed in ice-cold phosphate-buffered
saline (PBS, pH 7.4), quickly embedded in Tissue-Tek
TM O.C.T.
compound (Sakura Finetek, Torrance, CA, USA) and frozen in
dry ice-cooled isopropanol before storing at 270uC. Five mm thick
sections were cut using the Cryostat 1720 from Leitz, Wetzlar,
Germany and collected on SuperFrostHPlus slides (Menzel-Gla ¨ser,
Braunschweig, Germany). Sections were fixed for 5 minutes in
acetone at 220uC and air dried. After rinsing in Tris-buffered
saline (TBS, pH 7.6) containing 0.05% Tween 20, sections were
incubated with the DAKO Peroxidase Blocking Reagent (DAKO,
Glostrup, Denmark) for 15 minutes at 37uC followed by TBS
rinsing. Sections were then incubated for 30 minutes at 37uC with
affinity-purified antibodies (rabbit) against collagen type I (1:100
dilution) (Rockland, Gilbertsville, PA). After three washes in TBS
the primary antibody was labelled for 30 minutes using the
DAKO EnVision
TM +, Peroxidase, Rabbit K 4010 system and
3,39-diamino-benzidine tetrahydrochloride as the chromogen.
Sections were counterstained with hematoxylin for 1–2 minutes,
mounted and examined under a Leitz Aristoplan microscope.
RNA isolation and real time quantitative PCR
Total RNA was isolated from the LV of mice and LV biopsies
from patients using RNeasy mini kit (Cat# 74106, Qiagen Nordic,
Norway). RNA quality was determined using 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA). RNA integrity number
(RIN) .7.5 was required for further analysis. Reverse transcrip-
tion reactions were performed with iScript cDNA Synthesis Kit
(Bio-Rad Laboratories, Inc., Hercules, CA). Pre-designed Taq-
Man assays (Applied Biosystems, Foster City, CA) were used to
determine gene expression of a-skeletal actin (Mm00808218_g1),
ANP (Mm01255748_g1), BNP (Mm00435304_g1), RCAN1-4
(Mm01213406_m1) and GAPDH (Mm03302249_g1) in WT
and syndecan-4
2/2 mice three weeks after AB or SHAB, and
expression of syndecan-4 and RCAN1-4 (Hs01120954_m1) in
human myocardial biopsies (Hs01120909_m1). The results were
detected on an ABI PRISM 7900 Sequence Detection System
(Applied Biosystems).
Tissue extracts
LV tissue extract A. Frozen murine LV tissue was pulverized
in a mortar with liquid nitrogen before transfer to lysis buffer
(20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton) with protease (1 mM PMSF and Complete EDTA-free
tablets; Roche Diagnostics) and phosphatase inhibitors (1 mM
Na3VO4, 10 mM NaPP and 50 mM NaF) in a glass tube. The
samples were homogenized with a Polytron 1200 and centrifuged
at 70 0006g for 60 min at 4uC. Supernatants were collected and
stored at 270uC. LV tissue extract B. Frozen murine LV tissue
or human myocardial LV biopsies were homogenized using a
Polytron 1200 in a PBS buffer containing 1% Triton X-100, 0.1%
Tween20 and protease (Complete EDTA-free tablets) and
phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4),
incubated on ice for 30 min and centrifuged at 14 000–20 000 g
for 10 min. The resulting supernatants collected and stored at
270uC. Protein concentrations were determined by Micro BCA
Protein Assay Kit (Pierce, Rockford, IL).
Immunoprecipitation
LV extracts (500 mg tissue extract A) from WT mice 24 h after
SHAB or AB were incubated with antibodies (2 mg) and 30 ml
protein A/G agarose beads (Santa Cruz Biotechnology, Santa
Cruz, CA, sc-2003) overnight at 4uC. Immunocomplexes were
washed once for 10 min in immunoprecipitation (IP)-buffer
(20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
Triton), four times 10 min in IP-buffer with high salt (1 M) and
finally once for 10 min in IP-buffer, boiled in SDS loading buffer
and analyzed by immunoblotting. Rabbit IgG (sc-2027) and goat
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from HEK-293 extracts (in presence of 1.5 mM CaCl2) were
washed three times in lysis buffer (20 mM Hepes, pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.5% Triton). Immunoprecipitates
were analyzed by immunoblotting.
Isolation of neonatal mouse cardiomyocytes
Solutions used; Trypsin solution: 1.11 mg Trypsin powder
(Sigma, St.Louis, MO) mixed with 30 ml cold Hanks Balanced
Salt Solution (HBSS, Gibco-BRL, Gaithersburg, MD). Collagenase
solution: 23.25 mg collagenase Type-2 powder (Worthington
Biochemical, Lakewood, NJ) mixed with 100 ml HBSS. Light-
medium: 375 ml DMEM (Gibco-BRL), 125 ml M-199 (Gibco-
BRL), 5 ml 1006 penicillin/streptomycin/glutamine solution
(Sigma) and 5 ml 1 M HEPES (Gibco-BRL). Dark medium: Light
medium mixed with 25 ml horse serum (Gibco-BRL) and 12.5 ml
fetal bovine serum (Gibco-BRL). All solutions were filter sterilized.
The procedure is based on a protocol by Masahiko Hoshijima,
University of California, San Diego, CA. In brief, 40–60 neonatal
pups were quickly decapitated and their hearts removed and
placed in cold HBSS. The LV cut into pieces were digested for
166 min and 7610 min in 18 ml of collagenase solution. Each
resulting supernatant was transferred to a 50 ml conical tube with
cold dark medium on ice, containing serum to inactivate the
collagenase. The pooled supernatants were centrifuged at 1246g
for 6 min and the pellet resuspended in warm dark medium. The
cells were plated in 150 cm
2 flasks and incubated at 37uC for
2675 min for differential plating. The resulting suspension with
unattached cardiomyocytes was spun at 1246g for 10 min to
pellet cells. After resuspension of pellet in warm dark medium, the
cells were counted and plated in 6-well dishes or Omni Trays
(Omni Tray Cell Culture Treated w/Lid, Nalge Nunc Interna-
tional, Rochester, NY) coated with 0.2% gelatin (Sigma) added
0.1% fibronectin (Sigma) at a density of 2.5610
5 cells/ml, and
incubated at 37uC.
Treating cardiomyocytes with peptides
Isolated neonatal cardiomyocytes were cultured for two days in
6-well plates at a density of 0.6610
6 cells/ml. Cardiomyocytes
were treated with the arginine-coupled (50 mM) peptide (Genscript
Corp.) for 90 min and washed twice with RNase-free PBS before
being harvested in IP-buffer (20 mM Hepes, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100) with protease inhibitors
(Complete Mini EDTA-free tablets, Roche) or for quantification of
luciferase activity as described above. Harvested protein was
analyzed by immunoblotting. Peptide-treatment for longer time-
periods have been shown to result in considerable degradation of
the peptides [49].
Cyclic mechanical stretch of neonatal cardiomyocytes
Isolated neonatal cardiomyocytes were plated on collagen I
coated silicone membranes at a density of 2.5610
5 cells/ml. Cyclic
mechanical stretch was induced by stretching cells for 10 min–
24 hours (10%, 1 Hz) using the FlexCell Tension System FX-4000
(Dunn Labortechnik, Germany). Cyclosporin A (CsA) (SandIm-
mun Neoral, 500 ng/ml; 586107, Novartis, Switzerland) was used
as a calcineurin inhibitor with vehicle serving as control
(Cremophore, C5135, Sigma).
Quantification of 3
H-leucine incorporation
Isolated cardiomyocytes were left in culture for two-five days in
order to induce autonomous hypertrophy [18]. Five mCi/ml 3
H-
leucine (American Radiolabel Chemicals, MO) was added to the
medium at day two in culture. The cells were washed 6 times in
95% EtOH before harvested in 0.2 mol/l NaOH at day five in
culture. Serum-stimulated cells served as positive control. 3
H-
leucine incorporation was quantified by measuring counts per
minute (CPM) in duplicates from each sample at the Wallac
Winspectral 1414 Liquid Scintillation Counter (PerkinElmer,
MA). Samples were diluted in Pico-Fluor 40 (PerkinElmer).
Transfection of HEK-293 cells
HEK-293 cells were cultured in DMEM supplemented with
10% fetal calf serum, 100 U/ml penicillin, 1% non-essential
amino acids, and maintained in a 37uC, 5% CO2 humidified
incubator. The HEK-293 cells were transfected with HA-tagged
syndecan-4 full length, syndecan-4 S179A, syndecan-4 S179E,
His-tagged CnAa cloned into pcDNA 3.1/myc-HIS-A (custom
made, Genscript Corporation, Piscataway, NJ) using Lipofecta-
mine 2000 as instructed by the manufacturer (Invitrogen,
Carlsbad, CA). After 24 h total lysate (IP-buffer or lysis buffer),
or cytoplasmic, nuclear and membrane protein fractions were
harvested according to the protocol of the Compartmental Protein
Extraction Kit (2145, Chemicon/Millipore, Billerica, MA), and
analyzed by immunoblotting.
Pull-down experiments
Biotinylated peptides (5 mM) were incubated in total heart
extract (whole tissue lysate B) from WT mice overnight at 4uC.
Monoclonal anti-biotin-conjugated beads were added for 60 min
before the bead pellet was washed once for 10 min in IP-buffer,
four times 10 min in IP-buffer with high salt (1 M) and finally once
for 10 min in IP-buffer. To analyse for a direct interaction,
biotinylated peptides (10 mM) were incubated with 10 mg/ml
recombinant His-TF-CnA (custom made from Genscript Corpo-
ration, Piscataway, NJ) in a 100 ml binding buffer (10 mM NaCl,
20 mM Tris/HCl, pH 8, 6 mM MgCl2, 0,1% Triton X-100)
containing 1% BSA with gentle rocking for 3 h at 4uC. Twenty
five ml monoclonal anti-biotin-agarose (A-1559, Sigma, Saint
Louis, MO) was added and incubated with gentle rocking
overnight at 4uC. After collection by centrifugation, the beads
were washed three times with 1 ml binding buffer. Bound proteins
were extracted and boiled with 50 ml2 6 SDS sample buffer for
five min before analysis by immunoblotting.
Overlays
CnA overlays were conducted using active recombinant protein
expressed in E. coli (# 14-446, Upstate, Lake Placid, NY), native
CnA purified from bovine (# 14-390, Upstate) or endogenous
CnA in heart extract. Syndecan-4 overlays were conducted using a
biotin-syndecan-4 (171–198) peptide. Peptide arrays consisting of
either the cytoplasmic part of syndecan-4 or the whole of CnA
synthesized as partly overlapping 20-mer peptides (Biotechnology
Centre, Oslo, Norway) were first blocked in 5% non-fat dry milk
or 1% casein in Tris-Buffered Saline Tween 20 (TBST) for 2 h at
room temperature. The overlays were performed by incubating
overnight at 4uC and then washing the membrane 5 times in cold
phosphate-buffered saline with Tween 20 for 5 min at 4uC. These
were overlayed with CnA (active recombinant protein (Upstate,
Lake Placid, NY), native bovine CnA (Upstate) or endogenous
CnA from LV extract) or a biotin-syndecan-4 peptide, respective-
ly. Bound CnA or syndecan-4 was detected by immunoblotting.
Immunoblot analysis
Cell and tissue extracts and immunoprecipitates were analyzed
on 6%, 7.5%, 10%, 15% or 4–20% SDS/PAGE and blotted onto
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were blocked in 5% non-fat dry milk or 1% casein in TBST for
60 min at room temperature, incubated for 1–2 h at room
temperature or overnight at 4uC with primary antibodies, washed
five times five min in TBST and incubated with a horseradish-
peroxidase-conjugated secondary antibody. Blots were developed
by using ECL Plus (GE HealthCare, RPN2132). The chemilumi-
nescence signals were detected by Las-1000 or Las-4000 (both
Fujifilm, Tokyo, Japan). Actin, GAPDH or Coomassie Brilliant
Blue (Bio-Rad, R-250) was used as loading control.
Antibodies
Immunoblotting and immunoprecipitation were carried out
using anti-GSK-3b (1:1000 dilution, #9315, 27C10), anti-pGSK-
3b (1:1000 dilution, #9336, Ser9), Sapk/JNK (1:500 dilution,
#9252), anti-pSAPK/JNK (1:500 dilution, #9251, Thr183/
Tyr185), anti-p38 MAPK (1:500 dilution, #9212), anti-pp38
MAPK (1:500 dilution, #9211, Thr180/Tyr182) all from Cell
Signaling Technology, Danvers, MA, anti-D-Heparan Sulfate
(3G10 epitope, 1:1500 dilution, #370260, Seikagaku Corporation,
Tokyo, Japan), anti-syndecan-4 (1:200 dilution, sc-15350, used for
coimmunoprecipitation as epitope mapping demonstrated recog-
nition of amino acid sequence located to N-terminus of syndecan-4
(Fig. S3A)), anti-pS179-syndecan-4 (1:200 dilution, sc-22252-R),
anti-calcineurin A (1:200 dilution, sc-6124) all from Santa Cruz,
CA, anti-syndecan-4 (1:2000, #1420, a kind gift from A.
Horowitz, Angiogenesis Research Center and Section of Cardi-
ology, Dartmouth Medical School, Lebanon, NH and J. Li,
Division of Cardiology, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, epitope mapping demon-
strated specific recognition of amino acid sequence located to the
V-region in syndecan-4 (Fig. S3B)), anti-pS179-syndecan-4-HRP
(1:2000, #41144, custom made, Genscript Corporation, Piscat-
away, NJ), anti-EGFR (1:500, sc-03, Santa Cruz) anti-actin (1:500
dilution, sc-8432, Santa Cruz), anti-calsequestrin (1:2500 dilution,
PA1-913, Affinity BioReagents, Golden, CO) anti-PKC-a (1:200
dilution, sc-208, Santa Cruz, CA), anti-CaM (1:200, C7055,
Sigma), anti-pNFATc4 (1:200 dilution, sc-32630-R), anti-NFATc4
(1:200 dilution, sc-13036), anti-GAPDH (1:500 dilution, sc-20357),
anti-histone H4 (1:500 dilution, sc-8658) all from Santa Cruz, anti-
collagen type I (1:750 dilution, #1310-01, Southern Biotech,
Birmingham, AL), anti-collagen type III (1:3000 dilution, #600-
401-105, Rockland Immunochem., Gilbertsville, PA), anti-colla-
gen type VIII (1:500 dilution, #LC-C46861, LifeSpan Bioscienc-
es, Seattle, WA), anti-biotin-HRP (1:2500 dilution, A-0185) and
anti-biotin-conjugated beads (A-1559) both from Sigma. Horse-
radish peroxidase-conjugated anti-mouse (1:2500 dilution,
NA931V), donkey anti-rabbit IgG HRP affinity purified polyclon-
al antibody (1:2500 dilution, NA934V) both from GE HealthCare
and anti-goat IgGs (1:2500 dilution, HAF109, R&D Systems,
Minneapolis, MI) were used as secondary antibodies.
Peptide synthesis
Peptide arrays were synthesized on cellulose paper using a
Multipep automated peptide synthesizer (INTAVIS Bioanalytical
Instruments AG, Koeln, Germany) as described [50]. Arginine
coupled peptides were synthesized and purified to 95% purity
(Genscript Corp, Piscataway, NJ) [51]. Biotinylated peptides were
purified to 55–95% purity (Genscript Corporation or Biotechnol-
ogy Centre, Oslo, Norway).
Syn-4 (mem+cyt)-HA-Arg11: ERTEVLAALIVGGVVGIL-
FAVFLILLLVYRMKKKDEGSYDLGKKPIYKKAPTNEFYA-
YPYDVPDYA-R11
Arg9-Syn-4 (cyt): R9-RMKKKDEGSY DLGKKPIYKKAPT-
NEFYA
Biotinylated-syndecan-4: Biotin-RMKKKDEGSYDLGKK-
PIYKKAPTNEFYA (97% purity)
Biotinylated-pS179-syndecan-4: Biotin-RMKKKDEGpSYDL-
GKKPIYKKAPTNEFYA (95% purity)
Biotinylated-scrambled-syndecan-4: Biotin-GTKYPKMDRG-
KLFKYKAKPEDNESAYIK (70% purity) or Biotin-YYKPY-
FAGDLKKAKTPSNEI (85% purity)
Biotinylated-syndecan-1: Biotin-RMKKKDEGSYSLEEPKQ-
ANGGAYQKPTKQEEFYA (55–65% purity)
Biotinylated-syndecan-2: Biotin-RMRKKDEGSYDLGERK-
PSSAAYQKAPTKEFYA (85–90% purity)
Biotinylated-syndecan-3: Biotin-RMKKKDEGSYTLEEPKQ-
ASVTYQKPDKQEEFYA (60–70% purity)
Densitometric Analysis
Densitometric analysis was performed using Image Gauge 3.46,
Science lab 99 (Fujifilm, Tokyo, Japan), Image Quant (Fujifilm),
Scion Image (Scion Corporation, Frederick, Maryland) or ImageJ
(NIH).
Equipment and settings used for obtaining and
processing images
All figure layouts were made using Photoshop CS2 or CS3
(Adobe Systems Inc., San Jose, CA). Cropping of images was
carried out, and labeling and molecular size markers were added.
When electrophoretic blots were cropped, care was taken to retain
important bands, and at least six band widths above and below the
band of interest where possible. Occasionally, brightness and
contrast was adjusted equally across the entire image, including
controls, in Image Gauge or Photoshop CS2 or CS3.
Statistics
Data are expressed as group mean 6 s.e.m. and analyzed in
Statistica 6.0 or GraphPad Prism 5.0. All data were tested for
normality before comparisons between groups were made. All in
vivo and PCR data were examined using one-way ANOVA with
adjustment for multiple comparisons using the method of Hothorn
et al. [52]. Western data were analyzed using paired or unpaired
two-tailed Students t-test, or ANOVA with subsequent Newman-
Keuls or Bonferroni post hoc test. Differences were considered
significant for p,0.05.
Supporting Information
Figure S1 Activation of calcineurin-dependent nuclear factor of
activated T-cell (NFAT) signaling in cardiomyocytes in response to
cyclic mechanical stretch. (A) Relative NFAT luciferase activity in
neonatal cardiomyocytes from NFAT-luciferase reporter mice
subjected to cyclic mechanical stretch (MS) (10%, 1 Hz) for
10 min–24 hours (n=6–19). (B) Relative NFAT luciferase activity
in neonatal cardiomyocytes from NFAT-luciferase reporter mice
subjected to 24 hrs of cyclic mechanical stretch with and without
the calcineurin-inhibitor cyclosporin A (CsA) (n=8–19).Vehicle
(Veh) served as control. Values are mean 6 s.e.m.
(PDF)
Figure S2 Activation of nuclear factor of activated T-cell
(NFAT)-interacting, pro-hypertrophic signaling pathways in wild
type (WT) and syndecan-4
2/2 (Syn-4
2/2) mice in response to
pressure overload induced by aortic banding (AB). Representative
immunoblots and relative quantity of (A) calcineurin (CnA), (B)
glycogen synthase kinase (GSK)3-b and phosphorylated GSK3-b
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PLoS ONE | www.plosone.org 13 December 2011 | Volume 6 | Issue 12 | e28302(pGSK3-b), (C–D) Akt and phosphorylated Akt (pAKT), (E–F) c-
jun N-terminal kinases (JNK)2/3 and phosphorylated JNK2/3
(pJNK2/3), (G–H) extracellular signal regulated protein kinase
(ERK)1/2 and phosphorylated ERK1/2 (p ERK1/2) and (I–J)
p38 and phosphorylated p38 (pp38) in left ventricles (LV) from
WT and Syn-4
2/2 mice 24 h after AB or sham operation (SHAB)
(n=5–6). A calcineurin- rich cell lysate (Ramos) was used as
control for the calcineurin-positive protein band. Vinculin and
GAPDH were used as loading control. Values are mean 6 s.e.m.
(PDF)
Figure S3 Epitope mapping of syndecan-4 antibodies. Synde-
can-4 residues important for antibody binding were identified by
overlaying an array of immobilized syndecan-4 20-mer peptides
with (A) anti-syndecan-4, (sc-15350), (B) anti-syndecan-4 (#1420),
(C) anti-pS179-syndecan-4 (sc-22252-R) or (D) anti-pS179-synde-
can-4-HRP (# 41144). Underlined and bold amino acids indicate
the core epitope. (A) Anti-syndecan-4 (sc-15350) recognized the
amino acid sequence SIRETEVIDPQDLLEGRYFSGALPDD
located to the N-terminus of syndecan-4 consistent with the
source information from the producer (Santa Cruz) (n=1). (B)
Anti-syndecan-4 ( #1420) strongly and specifically recognized the
amino acid sequence KDEGSYDLGKKPIYKKAPTNEFYA
located to the cytoplasmic part of syndecan-4. Further mapping
revealed that the core epitope was located to the V-region in
syndecan-4 (underlined sequence in B) (n=3). Both pS179-
syndecan-4 antibodies (sc-22252-R, (n=2) and #41144 (n=3))
recognized pS179-syndecan-4 strongly (right panels in C and D,
respectively) compared to the non-phosphorylated syndecan-4 (left
panels). Consistent with our findings and according to Genscript,
the #41144 antibody is 32 times more specific for pS179-
syndecan-4 than non-phosphorylated syndecan-4.
(PDF)
Table S1 Animal characteristics, heart rates, left ventricular
pressures and echocardiographic measurements.
(DOC)
Table S2 Myocardial structure and neurohormonal changes.
(DOC)
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